Misplaced Pages

Legg–Calvé–Perthes syndrome
Other names	Perthes disease or Legg–Perthes disease
Radiograph of a person with Legg–Calvé–Perthes disease
Pronunciation	/ˈlɛɡ kælˈveɪ ˈpɜːrtiːz/
Specialty	Orthopedics
Symptoms	Pain in the hip, knee, ankle (hip pathology can refer pain to a normal knee or ankle), or groin.
Usual onset	4 to 8 years
Causes	Artery of the ligmentum teres femoris being constricted or even blocked too early
Diagnostic method	X-Ray
Treatment	Orthotics
Frequency	1/25,000 in boys and 1/100,000 in girls

Legg–Calvé–Perthes disease (LCPD) is a childhood hip disorder initiated by a disruption of blood flow to the head of the femur. Due to the lack of blood flow, the bone dies (osteonecrosis or avascular necrosis) and stops growing. Over time, healing occurs by new blood vessels infiltrating the dead bone and removing the necrotic bone which leads to a loss of bone mass and a weakening of the femoral head.

The condition is most commonly found in children between the ages of 4 and 8, but it can occur in children between the ages of 2 and 15. It can produce a permanent deformity of the femoral head, which increases the risk of developing osteoarthritis in adults. Perthes is a form of osteochondritis which affects only the hip. Bilateral Perthes, which means both hips are affected, should always be investigated to rule out multiple epiphyseal dysplasia.

Signs and symptoms

The condition is most commonly found in children between the ages of 4 and 10. Common symptoms include pain in the hip, knee, or ankle (since hip pathology can cause pain to be felt in a normal knee or ankle), or in the groin; this pain is exacerbated by hip or leg movement, especially internal hip rotation (with the knee flexed 90°, twisting the lower leg away from the center of the body). The range of motion is reduced, particularly in abduction and internal rotation, and the patient presents with a limp. Pain is usually mild. Atrophy of thigh muscles may occur from disuse and an inequality of leg length. In some cases, some activity can cause severe irritation or inflammation of the damaged area, including standing, walking, running, kneeling, or stooping repeatedly for an extended period. In cases exhibiting severe femoral osteonecrosis, pain is usually a chronic, throbbing sensation exacerbated by activity

The first signs are complaints of soreness from the child, which are often dismissed as growing pains, and limping or other joint guarding, particularly when tired. The pain is usually in the hip, but can also be felt in the knee (referred pain). In some cases, pain is felt in the unaffected hip and leg, due to the children favoring their injured side and placing the majority of their weight on their "good" leg. It is predominantly a disease of boys (4:1 ratio). Perthes is generally diagnosed between 5 and 12 years of age, although it has been diagnosed as early as 18 months. Typically, the disease is only seen in one hip, but bilateral Perthes is seen in about 10% of children diagnosed.

Cause

Perthes disease is a childhood hip disorder initiated by a disruption of blood flow to the head of the femur. Due to the lack of blood flow, the bone dies (osteonecrosis or avascular necrosis) and stops growing.

Legg believed the cause was impairment of blood supply to the femoral epiphysis, Calvé believed rickets, and Perthes deduced an infection possibly causing degenerative arthritis leads to LCP disease. Currently, a number of factors have been implicated, including heredity, trauma, endocrine dysfunction, inflammation, nutrition, and altered circulatory hemodynamics. Risk factors are not limited to impaired and disproportionate growth, low birth weight, delayed skeletal maturity, short stature, systemic hormonal changes, and low economic index. Although no one has identified the cause of Perthes disease, a reduction in blood flow to the joint is known.

The disease is theorized to include the artery of the ligamentum teres femoris being constricted or even blocked too early, not allowing for time when the medial circumflex femoral artery takes over. The medial circumflex femoral artery is the principal source of blood supply to the femoral head. LCP disease is a vascular restrictive condition of idiopathic nature. Symptoms like femoral head disfigurement, flattening, and collapse occur typically between ages four and ten, mostly male children of Caucasian descent. Children affected by LCP disease often display uneven gait and limited range of motion, and they experience mild to severe pain in the groin area. For example, a child may be six years old chronologically but may have grown only four years old in terms of bone maturity. The child may then engage in activities appropriate for a six-year-old child, but lacking the bone strength of an older child, these activities may lead to flattening or fracture of the hip joint. Genetics do not appear to be a determining factor, but a deficiency of blood factors with anticoagulant property used to disperse blood clots may lead to blockages in the vessels supplying the joint. A deficiency of protein C and protein S, which also act as blood anticoagulants, may also exist; if that were the case, their deficiency could cause clot formation in ligamentum teres femoris artery and hinder blood supply to the femoral head. However, no evidence of this has been found; over the years, many theories have been published, but none has stood up to professional research.

Pathology

Over time, healing occurs by new blood vessels infiltrating the dead bone and removing the necrotic bone which leads to a loss of bone mass and a weakening of the femoral head. The bone loss leads to some degree of collapse and deformity of the femoral head and sometimes secondary changes to the shape of the hip socket.

It is also referred to as idiopathic avascular osteonecrosis of the capital femoral epiphysis of the femoral head since the cause of the interruption of the blood supply of the head of the femur in the hip joint is unknown. Perthes can produce a permanent deformity of the femoral head, which increases the risk of developing osteoarthritis in adults. Perthes is a form of osteochondritis which only affects the hip, although other forms of osteochondritis can affect elbows, knees, ankles, and feet. Bilateral Perthes, which means both hips are affected, should always be investigated thoroughly to rule out multiple epiphyseal dysplasia.

Diagnosis

X-rays of the hip may suggest and/or verify the diagnosis. X-rays usually demonstrate a flattened, and later fragmented, femoral head. A bone scan or MRI may be useful in making the diagnosis in those cases where X-rays are inconclusive. Usually, plain radiographic changes are delayed six weeks or more from clinical onset, so bone scintigraphy and MRI are done for early diagnosis. MRI results are more accurate, i.e. 97–99% against 88–93% in plain radiography. If MRI or bone scans are necessary, a positive diagnosis relies upon patchy areas of vascularity to the capital femoral epiphysis (the developing femoral head).

Treatment

The goals of treatment are to decrease pain, reduce the loss of hip motion, and prevent or minimize permanent femoral head deformity so that the risk of developing a severe degenerative arthritis as an adult can be reduced. Assessment by a pediatric orthopaedic surgeon is recommended to evaluate risks and treatment options. Younger children have a better prognosis than older children.

Treatment has historically centered on removing mechanical pressure from the joint until the disease has run its course. Options include traction (to separate the femur from the pelvis and reduce wear), braces (often for several months, with an average of 18 months) to restore range of motion, physiotherapy, and surgical intervention when necessary because of permanent joint damage. To maintain activities of daily living, custom orthotics may be used. Overnight traction may be used in lieu of walking devices or in combination. These devices internally rotate the femoral head and abduct the leg(s) at 45°. Orthoses can start as proximal as the lumbar spine, and extend the length of the limbs to the floor. Most functional bracing is achieved using a waist belt and thigh cuffs derived from the Scottish-Rite orthosis. These devices are typically prescribed by a physician and implemented by an orthotist. Clinical results of the Scottish Rite orthosis have not been good according to some studies, and its use has gone out of favor. Many children, especially those with the onset of the disease before age 6, need no intervention at all and are simply asked to refrain from contact sports or games which impact the hip. For older children (onset of Perthes after age 6), the best treatment option remains unclear. Current treatment options for older children over age 8 include prolonged periods without weight bearing, osteotomy (femoral, pelvic, or shelf), and the hip distraction method using an external fixator which relieves the hip from carrying the body's weight. This allows room for the top of the femur to regrow.

While running and high-impact sports are not recommended during treatment for Perthes disease, children can remain active through a variety of other activities that limit mechanical stress on the hip joint. Swimming is highly recommended, as it allows exercise of the hip muscles with full range of motion while reducing the stress to a minimum. Cycling is another good option as it also keeps stress to a minimum. Physiotherapy generally involves a series of daily exercises, with weekly meetings with a physiotherapist to monitor progress. These exercises focus on improving and maintaining a full range of motion of the femur within the hip socket. Performing these exercises during the healing process is essential to ensure that the femur and hip socket have a perfectly smooth interface. This will minimize the long-term effects of the disease. Use of bisphosphonate such as zoledronate or ibandronate is currently being investigated, but definite recommendations are not yet available.

Perthes disease is self-limiting, but if the head of femur is left deformed, long-term problems can occur. Treatment is aimed at minimizing damage while the disease runs its course, not at 'curing' the disease. It is recommended not to use steroids or alcohol as these reduce oxygen in the blood which is needed in the joint. As those affected age, problems in the knee and back can arise secondary to abnormal posture and stride adopted to protect the affected joint. The condition is also linked to arthritis of the hip, though this appears not to be an inevitable consequence. Hip replacements are relatively common as the already damaged hip experiences routine wear; this varies by individual, but generally is required any time after age 50.

Prognosis

Children younger than six have the best prognosis, since they have time for the dead bone to revascularize and remodel, with a good chance that the femoral head will recover and remain spherical after resolution of the disease. Children who have been diagnosed with Perthes' disease after the age of ten are at a very high risk of developing osteoarthritis and coxa magna. When an LCP disease diagnosis occurs after age eight, a better outcome results with surgery rather than nonoperative treatments. Shape of femoral head at the time when Legg-Calvé Perthes disease heals is the most important determinant of risk for degenerative arthritis; hence, the shape of femoral head and congruence of hip are most useful outcome measures.

Epidemiology

Perthes' disease is one of the most common hip disorders in young children, occurring in roughly 5.5 of 100,000 children per year. The lifetime risk of a child developing the disease is about one per 1,200 individuals. Boys are affected about three to five times more often than girls. New cases of Perthes' disease rarely occur after age 14 years (if diagnosed after 14 years of age, then it is usually old disease from early in childhood or avascular necrosis from an alternative cause). White northern Europeans appear to be affected more frequently than other ethnicities, though a paucity of reliable epidemiology exists in the Southern Hemisphere. Children of those with the disease themselves may have a very slightly increased risk, though it is unclear if this is because of a genetic predisposition, or a shared environmental factor. It is most commonly seen in persons aged three to twelve years, with a median of six years of age. The UK incidence rates show an intriguing pattern with low incidence rates in London, and a progressive increase in disease in more northerly areas (maximal in Scotland). Some evidence suggests, at least in developed countries, more socioeconomically deprived communities have a greater risk of disease (a similar trend to diseases such as adult heart disease), though the reason for this remains unknown. One possible explanation that has been considered is tobacco smoke exposure, though this is significantly confounded by the strong socioeconomic gradient common to both smoking and Perthes' disease.

History

• 1897: The disease was first described by Karel Maydl (1853–1903).
• 1909: Henning Waldenström (1877–1972) described the disease, attributing it to tuberculosis.
• 1910: The disease was recognized as being unrelated to tuberculosis by three physicians working independently. Legg–Calvé–Perthes is named after these three doctors: Arthur Legg (1874–1939), Jacques Calvé (1875–1954), and Georg Perthes (1869–1927).

Research directions

In the UK in 2016, a nationwide study collected details of every case of Perthes' disease as part of the British Orthopaedic Surgery Surveillance (BOSS) Study. Every hospital in England, Scotland, and Wales which treated Perthes' disease colled details of new cases. This demonstrated the major variation in treatment across the UK, with no clear benefit of surgery over non-surgical care. In 2024, following on from the BOSS study, a nationwide randomised study was opened across the UK - OpNonSTOP .This is a study funded by the National Institute for Health Research (NIHR), that runs throughout the UK at specialist children's orthopaedic centres. The OpNonSTOP study compares surgical containment to active containment (optimised care without surgery). The study is expected to recruit patients between 2024 and 2027, and will be the only high-quality level-I study ever produced in Perthes' disease, influencing the care of children throughout the world.

Dogs

LCP disease is an avascular necrosis of the femoral head in small-breed dogs, usually those weighing up to 25 lbs. LCP disease was first described in veterinary literature by Tutt in 1935. Tutt described the disease as almost exactly what Waldenstromin (1909) described in humans. Small breeds, particularly Toy Poodles, Yorkshire Terriers, Pugs, Jack Russell Terriers, West Highland White Terriers, and Dachshunds can be affected. No sex predilection is seen in the dog as contrasted to humans, in whom an 80% male incidence of the disease is evident. Similar to children, however, the condition is usually unilateral, with only about 10–15% incidence of bilateral disease. The age of onset varies between 4 and 12 months, with a peak incidence around 7 months. The pathology of avascular necrosis followed by revascularization and bony remodeling of the femoral head in the dog certainly suggests a vascular etiology, though the cause of the condition is not completely understood. Hip pain is usually seen by the age of 6 to 8 months. The disease is bilateral in 12–16% of cases. X-rays are necessary to make the diagnosis and show increased opacity and focal lysis in the head of the femur, and later in the disease, collapse and fracture of the neck of the femur. The recommended treatment is surgical removal of the head of the femur, but conservative treatment (rest, exercise restriction, and pain medication) may be effective in a limited number of cases (less than 25%, according to some studies). In dogs, the prognosis is excellent with surgery. Prednisolone tablets may also be helpful.

References

1. Wenger DR, Ward WT, Herring JA (June 1991). "Legg-Calvé-Perthes disease". The Journal of Bone and Joint Surgery. American Volume. 73 (5): 778–788. doi:10.2106/00004623-199173050-00020. PMID 2045406.
2. Divi SN, Bielski RJ (April 2016). "Legg-Calvé-Perthes Disease". Pediatric Annals. 45 (4): e144–e149. doi:10.3928/00904481-20160310-03. PMID 27064472.
3. Legg-Calve-Perthes Disease Imaging at eMedicine
4. ^ Rodríguez-Olivas AO, Hernández-Zamora E, Reyes-Maldonado E (March 2022). "Legg-Calvé-Perthes disease overview". Orphanet Journal of Rare Diseases. 17 (1): 125. doi:10.1186/s13023-022-02275-z. PMC 8922924. PMID 35292045.
5. Yochum TR, Rowe LJ (1987). Essentials of Skeletal Radiology. Williams & Wilkins. p. 995. ISBN 0-683-09329-0.
6. ^ Bahmanyar S, Montgomery SM, Weiss RJ, Ekbom A (August 2008). "Maternal smoking during pregnancy, other prenatal and perinatal factors, and the risk of Legg-Calvé-Perthes disease". Pediatrics. 122 (2): e459–e464. doi:10.1542/peds.2008-0307. PMID 18625663. S2CID 12645569.
7. ^ Kim HK (November 2010). "Legg-Calvé-Perthes disease". The Journal of the American Academy of Orthopaedic Surgeons. 18 (11): 676–686. doi:10.5435/00124635-201011000-00005. PMID 21041802. S2CID 42235121.
8. Vosmaer A, Pereira RR, Koenderman JS, Rosendaal FR, Cannegieter SC (January 2010). "Coagulation abnormalities in Legg-Calvé-Perthes disease". The Journal of Bone and Joint Surgery. American Volume. 92 (1): 121–128. doi:10.2106/JBJS.I.00157. PMID 20048104.
9. ^ Kim HK (April 2012). "Pathophysiology and new strategies for the treatment of Legg-Calvé-Perthes disease". The Journal of Bone and Joint Surgery. American Volume. 94 (7): 659–669. doi:10.2106/JBJS.J.01834. PMID 22488623.
10. Anthony S, Munk R, Skakun W, Masini M (March 2015). "Multiple epiphyseal dysplasia". The Journal of the American Academy of Orthopaedic Surgeons. 23 (3): 164–172. doi:10.5435/JAAOS-D-13-00173. PMID 25667404. S2CID 38168231.
11. Laine JC, Martin BD, Novotny SA, Kelly DM (August 2018). "Role of Advanced Imaging in the Diagnosis and Management of Active Legg-Calvé-Perthes Disease". The Journal of the American Academy of Orthopaedic Surgeons. 26 (15): 526–536. doi:10.5435/JAAOS-D-16-00856. PMID 29939867. S2CID 49417062.
12. Kim HK, Herring JA (July 2011). "Pathophysiology, classifications, and natural history of Perthes disease". The Orthopedic Clinics of North America. 42 (3): 285–95, v. doi:10.1016/J.OCL.2011.04.007. PMID 21742140.
13. Joseph B (July 2011). "Prognostic factors and outcome measures in Perthes disease". The Orthopedic Clinics of North America. 42 (3): 303–15. doi:10.1016/j.ocl.2011.03.004. PMID 21742142.
14. http://www.nih.gov
15. Katz J (1984). Legg–Calvé-Perthes-Disease. New York: Praeger.
16. Young ML, Little DG, Kim HK (September 2012). "Evidence for using bisphosphonate to treat Legg-Calvé-Perthes disease". Clinical Orthopaedics and Related Research. 470 (9): 2462–2475. doi:10.1007/s11999-011-2240-0. PMC 3830104. PMID 22270467.
17. Johannesen J, Briody J, McQuade M, Little DG, Cowell CT, Munns CF (November 2009). "Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease". Bone. 45 (5): 898–902. doi:10.1016/j.bone.2009.04.255. PMID 19446052.
18. Seufert CR, McGrory BJ (October 2015). "Treatment of Arthritis Associated With Legg-Calve-Perthes Disease With Modular Total Hip Arthroplasty". The Journal of Arthroplasty. 30 (10): 1743–1746. doi:10.1016/j.arth.2015.04.025. PMID 25979188.
19. Agabegi ED, Agabegi SS (2008). Step-Up to Medicine. Step-Up Series. Hagerstwon, MD: Lippincott Williams & Wilkins. p. 83. ISBN 978-0-7817-7153-5.
20. Balasa VV, Gruppo RA, Glueck CJ, Wang P, Roy DR, Wall EJ, et al. (December 2004). "Legg-Calve-Perthes disease and thrombophilia". The Journal of Bone and Joint Surgery. American Volume. 86 (12): 2642–2647. doi:10.2106/00004623-200412000-00009. PMID 15590848. S2CID 30054597.
21. Perry DC, Machin DM, Pope D, Bruce CE, Dangerfield P, Platt MJ, Hall AJ (February 2012). "Racial and geographic factors in the incidence of Legg-Calvé-Perthes' disease: a systematic review". American Journal of Epidemiology. 175 (3): 159–166. doi:10.1093/aje/kwr293. PMID 22223709.
22. ^ Perry DC, Bruce CE, Pope D, Dangerfield P, Platt MJ, Hall AJ (May 2012). "Legg-Calvé-Perthes disease in the UK: geographic and temporal trends in incidence reflecting differences in degree of deprivation in childhood". Arthritis and Rheumatism. 64 (5): 1673–1679. doi:10.1002/art.34316. PMID 22143958.
23. Perry DC, Bruce CE, Pope D, Dangerfield P, Platt MJ, Hall AJ (December 2011). "Perthes' disease: deprivation and decline". Archives of Disease in Childhood. 96 (12): 1124–1128. doi:10.1136/archdischild-2011-300413. PMID 22080458. S2CID 206853890.
24. Barker DJ, Dixon E, Taylor JF (November 1978). "Perthes' disease of the hip in three regions of England". The Journal of Bone and Joint Surgery. British Volume. 60-B (4): 478–480. doi:10.1302/0301-620X.60B4.711792. PMID 711792.
25. Hall AJ, Barker DJ (March 1989). "Perthes' disease in yorkshire". The Journal of Bone and Joint Surgery. British Volume. 71 (2): 229–233. doi:10.1302/0301-620X.71B2.2925740. PMID 2925740.
26. Perry DC, Bruce CE, Pope D, Dangerfield P, Platt MJ, Hall AJ (December 2012). "Perthes' disease of the hip: socioeconomic inequalities and the urban environment". Archives of Disease in Childhood. 97 (12): 1053–1057. doi:10.1136/archdischild-2012-302143. PMID 23104772. S2CID 30496559.
27. Kealey WD, Moore AJ, Cook S, Cosgrove AP (March 2000). "Deprivation, urbanisation and Perthes' disease in Northern Ireland". The Journal of Bone and Joint Surgery. British Volume. 82 (2): 167–171. doi:10.1302/0301-620x.82b2.0820167. PMID 10755420.
28. Daniel AB, Shah H, Kamath A, Guddettu V, Joseph B (September 2012). "Environmental tobacco and wood smoke increase the risk of Legg-Calvé-Perthes disease". Clinical Orthopaedics and Related Research. 470 (9): 2369–2375. doi:10.1007/s11999-011-2180-8. PMC 3830089. PMID 22090357.
29. Chou DT, Ramachandran M (2016). "Chapter 7: Legg-Calvé-Perthes' disease: Historical note". In Aresti NA, Ramachandran M, Paterson JM, Barry M (eds.). Paediatric Orthopaedics in Clinical Practice. Springer. p. 105. ISBN 978-1-4471-6767-9.
30. Mostofi SB, ed. (2005). "Henning Waldenström". Who's who in orthopedics. London: Springer. p. 345. ISBN 9781852337865.
31. ^ Wainwright AM, Catterall A (2010). "Capter 27: Legg–Calvé–Perthes disease: Its name". In Benson M, Fixsen J, MacNicol M, Parsch K (eds.). Children's orthopaedics and fractures (3rd ed.). London: Springer. p. 465. ISBN 9781848826106.
32. Mostofi SB, ed. (2005). "Arthur Thornton Legg". Who's who in orthopedics. London: Springer. p. 189. ISBN 9781852337865.
33. Mostofi SB, ed. (2005). "Jacques Calvé". Who's who in orthopedics. London: Springer. p. 51. ISBN 9781852337865.
34. Mostofi SB, ed. (2005). "Georg Perthes". Who's who in orthopedics. London: Springer. p. 267. ISBN 9781852337865.
35. Perry, Daniel C.; Arch, Barbara; Appelbe, Duncan; Francis, Priya; Craven, Joanna; Monsell, Fergal P.; Williamson, Paula; Knight, Marian; on behalf of the BOSS collaborators (2022-04-01). "The British Orthopaedic Surgery Surveillance study: Perthes' disease: the epidemiology and two-year outcomes from a prospective cohort in Great Britain". The Bone & Joint Journal. 104-B (4): 510–518. doi:10.1302/0301-620X.104B4.BJJ-2021-1708.R1. ISSN 2049-4394. PMC 9020518. {{cite journal}}: |last9= has generic name (help)
36. "Search - NIHR Funding and Awards". fundingawards.nihr.ac.uk. Retrieved 2024-11-15.
37. Tutt JF (1935). "Tuberculosis of the hip joint in a cairn terrier". Vet Rec. 47: 428.
38. Waldenstrom H (1909). "Der oobere Tuberculose Collumherd". Orthop Chir. 24: 487. as tuberculosis of the hip.
39. Nunamaker DM (1985). "Legg-Calve-Perthes Disease". Textbook of Small Animal Orthopaedics. J.B. Lippincott Company. Archived from the original on 2011-09-05. Retrieved 2011-12-04.
40. Hulth A, Norberg I, Olsson SE (July 1962). "Coxa plana in the dog". The Journal of Bone and Joint Surgery. American Volume. 44-A (5): 918–930. doi:10.2106/00004623-196244050-00005. PMID 14036446.
41. Ettinger SJ, Feldman EC (2000). Textbook of Veterinary Internal Medicine. Vol. 2 (5th ed.). W.B. Saunders Company. pp. 1873, v. ISBN 0-7216-7258-2.
42. ^ Demko J, McLaughlin R (September 2005). "Developmental orthopedic disease". The Veterinary Clinics of North America. Small Animal Practice. 35 (5): 1111–35, v. doi:10.1016/j.cvsm.2005.05.002. PMID 16129135.

Further reading

• Nelitz M, Lippacher S, Krauspe R, Reichel H (July 2009). "Perthes disease: current principles of diagnosis and treatment". Deutsches Ärzteblatt International. 106 (31–32): 517–523. doi:10.3238/arztebl.2009.0517. PMC 2735835. PMID 19730720.

External links

• Syndromes affecting bones
• Rare diseases
• Skeletal disorders
• Osteonecrosis
• Syndromes in dogs